Etsy Inc vs Zimmer Biomet Holdings Inc — how do they compare? Etsy Inc trades at $76.34 (market cap $6.90B), while Zimmer Biomet Holdings Inc trades at $89.37 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.5× Etsy Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Etsy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ETSY | ZBH | |
|---|---|---|
Market Cap | $6.90B | $16.95B |
Volume | 2,923,867 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $103.98 |
52-Week Low | $44.05 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Enterprise Value | $8.85B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $74.90, up 4.77% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $73 and resistance at $76. Revenue reached $2.88B in 2025, with a net income margin of 5.65%. Recent news highlights AI integration and payment partnerships as growth catalysts, while analyst consensus remains positive with a $85.94 price target.
The outlook for ETSY is cautiously optimistic, supported by consistent earnings outperformance and strategic initiatives. Key risks include high debt levels and competitive e-commerce pressures. Upside potential exists if AI-driven personalization boosts user engagement, but investors should monitor margin sustainability and macroeconomic impacts on consumer spending.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
Latest headlines on both assets
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →